- Stocks
- Pharma & Healthcare
- Suven Life Sciences
Suven Life Sciences share price
NSE: SUVENPharma & HealthcareDrug Manufacturers - Specialty & Generic
Suven Life Sciences at a glance
Suven Life Sciences (NSE: SUVEN) closed at ₹290.50 on 19 Oct 2026, down 4.71% on the day. With a market capitalisation of ₹8,208 Cr, it ranks 617th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −146.1% in FY25. Over the past year the share price has risen 39.0%. Its 52-week range is ₹124.11 (24 Mar 2026) to ₹403.35 (1 Sep 2026); the last close is 28.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4 Cr (+90.9% year on year) and net profit −₹128 Cr, on a consolidated basis. Promoters held 65.47% of the company as of 8 Jul 2026.
Key numbers
- Market cap
- ₹8,208 CrRank 617 on NSE
- Price to book
- 22.48×FY25
- EPS (TTM)
- −₹14.89to Q1 FY27
- ROE
- −146.1%FY25
- ROCE
- −143.9%FY25
- Debt to equity
- 0FY25
- Net profit margin
- −2,415.1%FY25
- Book value / share
- ₹5.04FY25
- 52-week high
- ₹403.351 Sep 2026
- 52-week low
- ₹124.1124 Mar 2026
- 1-year return
- +39.0%
- RSI (14-day)
- 37.2
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −4.71% | +1.9% | −17.5% | −14.1% | +39.0% |
Suven Life Sciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹3 Cr | ₹2 Cr | ₹4 Cr |
| Revenue YoY | −16.0% | −34.3% | — | +85.1% | −64.2% | +74.5% | +3.4% | +90.9% |
| Net profit | −₹50 Cr | −₹39 Cr | −₹44 Cr | −₹52 Cr | −₹77 Cr | −₹102 Cr | −₹46 Cr | −₹128 Cr |
| Net profit YoY | — | — | — | — | — | — | — | — |
| Net margin | −1,931.5% | −2,429.8% | −2,989.1% | −2,755.1% | −8,403.3% | −3,627.0% | −3,000.0% | −3,574.5% |
| EPS | −₹2.27 | −₹1.79 | −₹2.02 | −₹2.36 | −₹3.48 | −₹4.55 | −₹2.02 | −₹4.84 |
Suven Life Sciences financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹13 Cr | ₹12 Cr | ₹14 Cr | ₹12 Cr | ₹7 Cr |
| Operating profit | −₹106 Cr | −₹77 Cr | −₹122 Cr | −₹124 Cr | −₹114 Cr | −₹161 Cr |
| Net profit | −₹94 Cr | −₹72 Cr | −₹122 Cr | −₹118 Cr | −₹105 Cr | −₹161 Cr |
| EPS (₹) | −₹7.00 | −₹6.00 | −₹10.00 | −₹7.00 | −₹5.00 | −₹7.00 |
| Cash from operations | −₹194 Cr | −₹96 Cr | −₹128 Cr | −₹103 Cr | −₹115 Cr | −₹154 Cr |
| Total debt | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹143 Cr | ₹108 Cr | ₹96 Cr | ₹375 Cr | ₹270 Cr | ₹110 Cr |
Suven Life Sciences shareholding pattern
| Holder | 30 Sep 2025 | 31 Dec 2025 | 6 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 | 8 Jul 2026 |
|---|---|---|---|---|---|---|
| Promoters | 67.36% | 67.36% | 70.15% | 70.15% | 70.08% | 65.47% |
| Foreign institutions | 1.18% | 1.07% | 0.81% | 0.91% | 0.57% | 0.48% |
| Domestic institutions | 3.39% | 3.39% | 4.62% | 4.62% | 2.93% | 2.73% |
| Non-institutions | 28.07% | 28.18% | 24.41% | 24.32% | 26.43% | 31.32% |
Suven Life Sciences vs peers
The listed Pharma & Healthcare companies nearest to Suven Life Sciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| STARStrides Pharma Science | ₹1,019.90 | −2.32% | +20.3% | ₹9,401 Cr | 16.9 | — |
| YATHARTHYatharth Hospital & Trauma Care Services | ₹968.00 | −2.52% | +19.5% | ₹9,327 Cr | 53.1 | — |
| HCGHealthcare Global Enterprises | ₹570.00 | −3.39% | −16.4% | ₹8,510 Cr | — | — |
| SUVENSuven Life Sciences | ₹290.50 | −4.71% | +39.0% | ₹8,208 Cr | — | — |
| SANOFICONRSanofi Consumer Healthcare India | ₹3,473.40 | −2.39% | −25.8% | ₹7,999 Cr | 31 | — |
| AARTIPHARMAarti Pharmalabs | ₹835.00 | −4.78% | +0.3% | ₹7,572 Cr | 43.4 | — |
| THYROCAREThyrocare Technologies | ₹469.95 | −3.12% | +11.1% | ₹7,480 Cr | 46.1 | — |
Ask anything about Suven Life Sciences
Pivot answers on the live chart with evidence you can check, and tests strategies against SUVEN's own history. Try: “Why has SUVEN moved over the last three months?” · “Backtest a 50-day moving-average crossover on SUVEN over five years” · “Compare SUVEN with STAR on margins and valuation”
Frequently asked questions about Suven Life Sciences
What is the share price of Suven Life Sciences today?
Suven Life Sciences (NSE: SUVEN) last closed at ₹290.50 on 19 Oct 2026. Its 52-week high is ₹403.35 and its 52-week low is ₹124.11.
What is the market cap of Suven Life Sciences?
Suven Life Sciences' market capitalisation is ₹8,208 Cr (₹8,208 Cr) at the 19 Oct 2026 close, ranking 617th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Suven Life Sciences?
Return on equity was −146.1% in FY25 and return on capital employed was −143.9% in FY25 (consolidated figures).
Is Suven Life Sciences a debt-free company?
Suven Life Sciences is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Suven Life Sciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Suven Life Sciences reported revenue of ₹4 Cr, +90.9% year on year, and net profit of −₹128 Cr.
How has Suven Life Sciences stock performed over the last year?
Suven Life Sciences' share price has risen 39.0% over the past year, −14.1% over three months and −17.5% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Suven Life Sciences?
As of 8 Jul 2026: promoters 65.47%, foreign institutions 0.48%, domestic institutions 2.73%, non-institutions 31.32%.
Who are Suven Life Sciences' competitors?
The listed Pharma & Healthcare companies closest to Suven Life Sciences by market cap are Strides Pharma Science, Yatharth Hospital & Trauma Care Services, Healthcare Global Enterprises, Sanofi Consumer Healthcare India, Aarti Pharmalabs and Thyrocare Technologies.
Is Suven Life Sciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Suven Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUVEN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text